Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARa, respectively. Both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX-1 designed to activate the cGAS/STING pathway selectively. Tempest is headquartered in South San Francisco and supported by notable healthcare investors.
Company profile
Ticker
TPST
Exchange
Website
CEO
Julia Owens
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Millendo Therapeutics, Inc., OvaScience, Inc.
SEC CIK
Corporate docs
Subsidiaries
TempestTx, Inc. • Millendo Therapeutics US, Inc. ...
IRS number
451472564
TPST stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
29 Dec 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update
8 Nov 22
8-K
Departure of Directors or Certain Officers
23 Sep 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
8-K
Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update
15 Aug 22
S-8
Registration of securities for employees
21 Jun 22
8-K
Departure of Directors or Certain Officers
21 Jun 22
8-K
Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance
9 Jun 22
424B3
Prospectus supplement
27 May 22
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 43.16 mm | 43.16 mm | 43.16 mm | 43.16 mm | 43.16 mm | 43.16 mm |
| Cash burn (monthly) | 2.94 mm | 1.38 mm | 2.92 mm | 2.75 mm | 3.02 mm | 2.71 mm |
| Cash used (since last report) | 12.80 mm | 6.02 mm | 12.72 mm | 11.98 mm | 13.16 mm | 11.81 mm |
| Cash remaining | 30.35 mm | 37.14 mm | 30.44 mm | 31.18 mm | 30.00 mm | 31.35 mm |
| Runway (months of cash) | 10.3 | 26.8 | 10.4 | 11.3 | 9.9 | 11.5 |
Institutional ownership, Q2 2022
51.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 20 |
| Opened positions | 4 |
| Closed positions | 2 |
| Increased positions | 4 |
| Reduced positions | 5 |
| 13F shares | Current |
|---|---|
| Total value | 15.52 mm |
| Total shares | 5.46 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Versant Venture Capital VI | 2.12 mm | $7.65 mm |
| EcoR1 Capital | 1.03 mm | $2.22 mm |
| Rock Springs Capital Management | 823.65 k | $1.77 mm |
| FMR | 647.90 k | $1.38 mm |
| Vanguard | 248.27 k | $534.00 k |
| LAV Regulus | 153.74 k | $812.00 k |
| FIL | 129.58 k | $275.00 k |
| BLK Blackrock | 83.07 k | $178.00 k |
| Roche Finance | 72.61 k | $383.00 k |
| Ikarian Capital | 61.83 k | $132.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Jan 23 | Justin Trojanowski | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.23 | 20,300 | 24.97 k | 20,300 |
| 3 Jan 23 | Nicholas Maestas | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.23 | 38,425 | 47.26 k | 38,425 |
| 3 Jan 23 | Stephen R Brady | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.23 | 177,300 | 218.08 k | 177,300 |
| 3 Jan 23 | Samuel Whiting | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.23 | 69,700 | 85.73 k | 69,700 |
| 3 Jan 23 | Thomas W. Dubensky | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.23 | 102,700 | 126.32 k | 102,700 |
News
HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Maintains $35 Price Target
8 Feb 23
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
18 Jan 23
Why Broadwind Shares Are Trading Higher By 85%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
11 Jan 23
12 Health Care Stocks Moving In Wednesday's Intraday Session
11 Jan 23
Stocks That Hit 52-Week Lows On Thursday
29 Dec 22